The risk-benefit equation: when to initiate treatment.
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D001145:Arrhythmias, Cardiac / Q000139:chemically induced; D001581:Benzothiadiazines; D001794:Blood Pressure; D002986:Clinical Trials as Topic; D003645:Death, Sudden / Q000209:etiology; D003971:Diastole; D004151:Dipeptides / Q000627:therapeutic use; D004232:Diuretics; D004311:Double-Blind Method; D004656:Enalapril; D005500:Follow-Up Studies; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000188:drug therapy*; D009203:Myocardial Infarction / Q000517:prevention & control; D012306:Risk; D049993:Sodium Chloride Symporter Inhibitors / Q000009:adverse effects
D000319:Adrenergic beta-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D001581:Benzothiadiazines; D004151:Dipeptides; D004232:Diuretics; D049993:Sodium Chloride Symporter Inhibitors; D004656:Enalapril